Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

Abstract Views: 1696
PDF: 1002
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Scrivo, R., Conti, F., Spinelli, F., Truglia, S., Magrini, L., Di Franco, M., Ceccarelli, F., & Valesini, G. (2009). Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo, 61(2), 107–117. https://doi.org/10.4081/reumatismo.2009.107